Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 15/20 | 0.47 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487418 | 0.89 | CXCR2 (0.51) | CXCR2CXCR1ADORA3 | |
| SCHEMBL1487315 | 0.88 | CXCR2 (0.49) | CXCR2CXCR1ADORA3 | |
| SCHEMBL1487243 | 0.87 | CXCR2 (0.46) | CXCR2CXCR1ALDH1A1LMNA | |
| SCHEMBL1487252 | 0.83 | CXCR2 (0.54) | CXCR2CXCR1ADORA3ALDH1A1LMNA | |
| SCHEMBL1487287 | 0.83 | CXCR2 (0.48) | CXCR2CXCR1ALDH1A1 | |
| SCHEMBL1487393 | 0.80 | CXCR2 (0.47) | CXCR2CXCR1ADORA3ALDH1A1 | |
| SCHEMBL1487174 | 0.80 | CXCR2 (0.49) | CXCR2CXCR1ALDH1A1LMNACYP3A4 | |
| SCHEMBL1487270 | 0.80 | CXCR2 (0.63) | CXCR2CXCR1LMNA | |
| SCHEMBL1487189 | 0.79 | CXCR2 (0.62) | CXCR2CXCR1ADORA3ALDH1A1 | |
| SCHEMBL9972770 | 0.79 | CXCR2 (0.43) | CXCR2CXCR1ADORA3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722883-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2014-05-13 | — | — | US | disclosed |
| EP-1809624-B1 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2013-11-20 | — | — | EP | disclosed |
| US-20130203991-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA R&D ALDERLY PARK (GB) | 2013-08-08 | — | — | US | disclosed |
| US-8410123-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2013-04-02 | — | — | US | disclosed |
| US-8269002-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| US-20120157431-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2012-06-21 | — | — | US | disclosed |
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| EP-2311827-A1 | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators. | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2301933-A1 | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-7838675-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2010-11-23 | — | — | US | disclosed |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157431-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | CXCR2 4/4885CXCR1 1/4885PTGS2 2208/4885 |
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | CXCR2 4/4885CXCR1 1/4885PTGS2 2208/4885 |
| US-20130203991-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | CXCR2 4/4885CXCR1 1/4885PTGS2 2208/4885 |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | CXCR2 4/4885CXCR1 1/4885PTGS2 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.